• SCG Cell Therapy GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • moc.llecgcs@ed.ofni
SCG Management

SCG Cell Therapy GmbH

Dr. Karin Wisskirchen, Managing Director & Head of Research
Dr. Susanne Wilde, Head of Preclinical Research
Dr. Gregory Fanning, Acting-CEO

About SCG Cell Therapy

SCG is a rapidly evolving clinical stage biotechnology company focusing on the development of novel immunotherapies for patients with infections and its associated cancers. Established and headquartered in Singapore, SCG has a strong footprint and scientific network in Singapore, China and Germany. The company develops T cell therapies, bispecific antibodies, and therapeutic vaccines for Hepatitis B Virus, Helicobacter Pylori and Human Papilloma Virus infection and its associated cancers, which attribute to high burden of diseases worldwide. SCG’s scientific founder is Prof. Dr. Ulrike Protzer, a leading virologist and director of the Institute of Virology of the Technical University of Munich and of the Institute of Virology of the Helmholtz Center Munich.

What is your motivation?

Our main driver in SCG is to make a difference to patients and their families by designing, testing and developing new immunotherapies to treat infection and its associated cancers. Founded out of research conducted in Germany, we are committed to converting this strong scientific foundation to therapeutic products and creating and maintaining a culture of excellence in scientific research and production development.

“We are pleased to be part of the IZB family, a leading innovation center in Europe and are looking forward to building a strong research team with local talent and connecting our global team to the renowned scientific community of Munich.”

Dr. Karin Wisskirchen, Managing Director & Head of Research
Dr. Susanne Wilde, Head of Preclinical Research
Dr. Gregory Fanning, Acting-CEO